

## SUBSCRIPTION AGREEMENT


### CONTRACT DETAILS (I)

<b>Oxford Economics:</b>	Oxford Economics Limited, incorporated and registered in England and Wales with company number 01557776 whose registered office is at Abbey House, 121 St Aldates, Oxford, OX1 1HB, UK
<b>Customer:</b>	Department for International Trade whose registered office is at 3 Whitehall Place, Westminster, London, SW1A 2HP
<b>Subscription Services:</b>	<ol style="list-style-type: none"><li>1. Global Economic Model</li><li>2. Global Industry Model</li><li>3. Global Economic Databank</li></ol> <p>Provided by Oxford Economics to the Customer under this Agreement via the <a href="https://oxfordeconomics.com">oxfordeconomics.com</a> domain or any other website notified to the Customer by Oxford Economics from time to time. Subscription Services may include Reports and Data and/or access to Software (as defined in the Terms and Conditions).</p>
<b>Subscription Term:</b>	This Agreement will commence on 27 <sup>th</sup> April 2021 (the <b>Commencement Date</b> ) and, unless otherwise terminated in accordance with the terms of this Agreement, will run for an initial period of 12 months and, thereafter, shall automatically renew for successive periods of 12 months, unless written notification of termination is given at least 45 days before an anniversary of the Commencement Date.
<b>Subscription Fees:</b>	<p>The Subscription Fees shall amount to a total of £33,200 in the first 12 months, plus applicable taxes.</p> <p>The Subscription Fees shall revert to £43,200, plus applicable taxes, after the initial 12 month <span style="background-color: black; color: black;">[REDACTED]</span></p>
<b>Payment:</b>	<p>Oxford Economics shall invoice the Customer on the Commencement Date for the Subscription Fees payable in respect of the first 12 months; and prior to each anniversary of the Commencement Date for the Subscription Fees payable in respect of the next 12-month period.</p> <p>Payment terms: 30 days from date of invoice.</p>
<b>Number of User Subscriptions / Specified Teams and Location:</b>	Access to these services will be available for up to <b>10</b> users, within the Customer's office in London.

<b>Permitted Purpose:</b>	Internal business operations
---------------------------	------------------------------

[REDACTED]

[REDACTED]













[The following text is a dense, continuous block of characters and symbols, likely representing a corrupted or redacted document. It contains no legible words or phrases.]

the 1990s, the incidence of *S. flexneri* has increased in the United Kingdom [10]. In the United States, *S. flexneri* has been reported as the most common serotype in children with acute bacterial dysentery [11].

There is a paucity of data on the epidemiology of *S. flexneri* in the United Kingdom. In the 1980s, *S. flexneri* was the most commonly isolated serotype from patients with acute bacterial dysentery in the United Kingdom [12]. In the 1990s, *S. flexneri* was the most commonly isolated serotype from patients with acute bacterial dysentery in the United Kingdom [13].

The aim of this study was to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom. The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom. The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom.

The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom. The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom.

The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom. The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom.

The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom. The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom.

The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom. The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom.

The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom. The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom.

The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom. The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom.


The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom. The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom.

The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom. The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom.

The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom. The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom.

The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom. The study was designed to determine the prevalence of *S. flexneri* in patients with acute bacterial dysentery in the United Kingdom.





the 1990s, the number of people in the UK who are aged 65 and over has increased by 1.5 million (1990–1999) and is projected to increase by a further 1.5 million by 2010 (Office for National Statistics, 2000). The number of people aged 65 and over in the UK is projected to increase from 10.5 million in 1999 to 12.5 million in 2010, with the number of people aged 75 and over increasing from 4.5 million to 6.5 million in the same period (Office for National Statistics, 2000).

There is a growing awareness of the need to develop strategies to meet the needs of the ageing population. The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'. The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'. The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'.

The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'. The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'. The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'.

The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'. The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'. The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'.

The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'. The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'. The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'.

The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'. The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'. The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'.

The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'. The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'. The Department of Health (2000) has identified the need to develop a 'new paradigm' for the care of the elderly, one that is based on the principles of 'active ageing' and 'positive ageing'.



[The following text is a dense, continuous block of text, likely a scan of a document page. It is mostly illegible due to extreme blurring and low contrast. The text appears to be a single paragraph or a series of lines of prose, but the specific words and sentences cannot be transcribed accurately.]

**Billing:** *(if as above, please leave blank)*

Billing Contact	Job Title and Department
-----------------	--------------------------

Billing Address (if different to above)
---

Phone Number	E-mail
--------------	--------

EU VAT number (if relevant)
-----------------------------

Advice for billing: (PO number, Accounts Payable....)
---